Caprock Group, Inc. Intellia Therapeutics, Inc. Transaction History
Caprock Group, Inc.
- $3.21 Billion
- Q1 2025
A detailed history of Caprock Group, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Caprock Group, Inc. holds 10,068 shares of NTLA stock, worth $83,363. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,068Holding current value
$83,363% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding NTLA
# of Institutions
344Shares Held
98.4MCall Options Held
784KPut Options Held
713K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$108 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$89 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$79.5 Million0.0% of portfolio
-
State Street Corp Boston, MA4.51MShares$37.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.8MShares$31.5 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $629M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...